Compare Amylx Pharmaceuticals Inc (AMLX) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Bath & Body Works Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Bath & Body Works Inc trades at $18.99 (market cap $3.89B). The key difference: Bath & Body Works Inc is the larger of the two by market cap, and Bath & Body Works Inc pays a 4.14% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BBWI | |
|---|---|---|
Market Cap | $2.53B | $3.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $31.87 |
52-Week Low | $7.82 | $14.85 |
Enterprise Value | $2.28B | $7.79B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
BBWI trades at $20.36, up 1.09% daily, with a bearish technical signal but strong fundamentals including a low P/E of 5.78 and net income margin of 10.03%. Recent earnings show mixed beats, while cash flow trends improved in 2026 forecasts. The company expands globally via Ulta Beauty partnerships and Brazil entry, supporting growth narratives amid revenue declines from $7.9B in 2022 to $7.3B in 2025.
Outlook balances deep value with execution risks; analyst consensus price target of $22.11 implies upside, but high debt and revenue pressures require monitoring turnaround initiatives. Opportunities lie in margin strength and expansion, while risks include competitive retail headwinds and liability management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
